Drug
Darleukin clinical trials
Also written L19IL2 and L19-IL2.
Keep track of what changes. Save the darleukin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 3
Philogen S.p.A. (8) · Maastricht Radiation Oncology (2) · Maastricht University Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses darleukin is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid TumorsRecruitingPhase 1Philogen S.p.A.NCT06640413Written as L19IL2
- Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsRecruitingPhase 2Philogen S.p.A.NCT06284590Written as L19IL2
- L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)RecruitingPhase 2Philogen S.p.A.NCT07227350Written as L19IL2
- Intratumoral Administration of Daromun in Non-melanoma Skin Cancer PatientsRecruitingPhase 2Philogen S.p.A.NCT04362722Written as L19IL2 +L19TNF
- IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II StudyTerminatedPhase 2Maastricht University Medical CenterNCT03705403Written as Darleukin
- Neoadjuvant L19IL2/L19TNF- Pivotal StudyActive, not recruitingPhase 3Philogen S.p.A.NCT02938299Written as L19IL2 + L19TNF
- Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid TumorCompletedPhase 1Maastricht Radiation OncologyNCT02086721Written as L19-IL2
- Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)WithdrawnPhase 2Maastricht Radiation OncologyNCT02735850Written as L19-IL2
- Intratumoral Administration of L19IL2/L19TNFCompletedPhase 2Philogen S.p.A.NCT02076633Written as L19IL2+L19TNF
- A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid TumoursCompletedPhase 1/2Philogen S.p.A.NCT01058538Written as L19IL2
- Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic MelanomaTerminatedPhase 2Philogen S.p.A.NCT01055522Written as Arm 1: L19IL2 + Dacarbazine
Given in every arm · 1 — darleukin is usual care beside what is tested
Codes
What other systems call darleukin · ClinicalTrials.gg INT014506
- UNII (FDA) 2OQ3OPV2F8DARLEUKINOne source FDA
- NCI Thesaurus C90546DarleukinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2OQ3OPV2F8 | DARLEUKIN | One source FDA |
| NCI Thesaurus | C90546 | Darleukin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.